Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 7/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | RARA | P10276 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | MTOR | P42345 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | PPARA | Q07869 | 3/20 | 0.58 |
| ▸ | PPARG | P37231 | 2/20 | 0.58 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.56 |
| ▸ | LPL | P06858 | 1/20 | 0.55 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1876486 | 1.00 | RARB (0.59) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL11442846 | 1.00 | RARB (0.59) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL27414335 | 1.00 | RARB (0.59) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL15766204 | 1.00 | RARB (0.59) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL15174619 | 1.00 | RARB (0.59) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL9812591 | 0.98 | RARB (0.58) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL443913 | 0.98 | RARB (0.58) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL31124111 | 0.93 | FOLH1 (0.58) | RARBPPARAPPARG | |
| SCHEMBL3387825 | 0.93 | FOLH1 (0.58) | RARBPPARAPPARG | |
| SCHEMBL9789538 | 0.91 | PPARA (0.65) | MAPTPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20210002202-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses Thereof | PROMETIC BIOSCIENCES, INC. (CA) | 2021-01-07 | — | — | US | disclosed |
| US-20210002202-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses Thereof | PROMETIC BIOSCIENCES, INC. (CA) | 2021-01-07 | — | — | US | disclosed |
| EP-3443957-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | LIMINAL BIOSCIENCES LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| US-10815183-B2 | Substituted aromatic compounds and pharmaceutical uses thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2020-10-27 | — | — | US | disclosed |
| US-10815183-B2 | Substituted aromatic compounds and pharmaceutical uses thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2020-10-27 | — | — | US | disclosed |
| US-10683277-B2 | Triazole derivatives as P2Y14 receptor antagonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-06-16 | — | — | US | disclosed |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| WO-2010127440-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | PROMETIC BIOSCIENCES INC. (CA) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010127440-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | PROMETIC BIOSCIENCES INC. (CA) | 2010-11-11 | — | — | WO | disclosed |
| EP-0672746-B1 | Oxime ethers and perfume and flavouring compositions containing them | GIVAUDAN SA (CH) | 2002-05-29 | — | — | EP | disclosed |
| EP-0684299-B1 | Dihydrofarnesal | GIVAUDAN SA (CH) | 2000-11-22 | — | — | EP | disclosed |
| US-5942272-A | 2(3)-DIHYDROFARNESAL USED TO FLAVOR FOODS AND IN PERFUMES AND PERSONAL CARE PRODUCTS; FLOWERY ODOR | GIVAUDAN-ROURE (INTERNATIONAL) SA (CH) | 1999-08-24 | — | — | US | disclosed |
| EP-0738700-A1 | CIS-3-HEXENAL CIS-3-HEXENYL ACETAL COMPOUND, PROCESS FOR PRODUCING THE SAME, AND FLAVOR/TASTE IMPARTING AGENT, FLAVOR/TASTE RETAINING AGENT AND PERFUME COMPOSITION EACH CONTAINING THE SAME | NIPPON ZEON CO., LTD. (JP) | 1996-10-23 | — | — | EP | disclosed |
| EP-0684299-A2 | Dihydrofarnesal | GIVAUDAN-ROURE (INTERNATIONAL) S.A. (CH) | 1995-11-29 | — | — | EP | disclosed |
| EP-0672746-A1 | Oxime ethers and perfume and flavouring compositions containing them | GIVAUDAN-ROURE (INTERNATIONAL) S.A. (CH) | 1995-09-20 | — | — | EP | disclosed |
| US-5422360-A | Hydrazonoimidazolidin-4-one derivatives; treatment of diabetes and aging disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-06-06 | — | — | US | disclosed |
| EP-0531812-A1 | Maillard reaction inhibitor, process for producing it, composition containing it and the use thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | RARB 2259/4885MEN1 4055/4885ALDH1A1 2776/4885 |
| US-10815183-B2 | Substituted aromatic compounds and pharmaceutical uses thereof | TYR, PAH, REN | RARB 2749/4885MEN1 4643/4885ALDH1A1 190/4885 |
| US-20210002202-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses Thereof | TYR, PAH, REN | RARB 2749/4885MEN1 4643/4885ALDH1A1 190/4885 |
| US-10683277-B2 | Triazole derivatives as P2Y14 receptor antagonists | GPR119, P2RY14, P2RY4 | RARB 3005/4885MEN1 2800/4885ALDH1A1 1845/4885 |
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | RARB 1105/4885MEN1 1517/4885ALDH1A1 3473/4885 |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | RARB 2259/4885MEN1 4055/4885ALDH1A1 2776/4885 |
| US-10597391-B2 | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof | NR1H4, FXR1, SLC10A1 | RARB 877/4885MEN1 4363/4885ALDH1A1 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.